Zhou Jingyu, Yan Yi, Guo Lei, Ou Huiying, Hai Jian, Zhang Chaojie, Wu Zhaoyun, Tang Lili
Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. E-mail.
Saudi Med J. 2014 Nov;35(11):1324-30.
To determine the outcome of patients with luminal A, luminal B, human epidermal growth factor receptor-2 (HER-2) positive, and triple negative molecular subtypes of inflammatory breast cancer (IBC) using a retrospective analysis.
This study was conducted between February 2004 and February 2010 in 3 different hospitals in China. The clinical outcomes, pathological features, and treatment strategies were analyzed in 67 cases of IBC without distant metastases. A chi-square test and one-way ANOVA were used to assess outcomes between different subtypes. Overall survival (OS) was analyzed using the Kaplan-Meier method and multivariate analysis was conducted using the Cox regression model.
The 2-year OS rate was 55% for the entire cohort. Median OS time among patients with luminal A was 35 months, luminal B was 30 months, HER-2 positive was 24 months, and triple negative subtypes was 20 months, and were significantly different from each other (p=0.001). Using multivariate analysis, luminal A had 76% (p=0.037), luminal B had 54% (p=0.048), and HER-2 positive subtypes had 47% (p=0.032) decreased risk of death compared with the triple negative subtype. Furthermore, elevated Ki-67 labeling was associated with increased risk of death, while the surgical treatment significantly improved patient survival.
Breast cancer subtypes are associated with distinct outcomes in IBC patients. Patients that presented with triple negative IBC had poorer outcome than luminal A, luminal B, and HER-2 subtypes. These results indicate that IBC is a heterogeneous disease similar to the conventional breast cancer.
通过回顾性分析确定炎性乳腺癌（IBC）的腔面A型、腔面B型、人表皮生长因子受体2（HER-2）阳性型和三阴性分子亚型患者的预后。
本研究于2004年2月至2010年2月在中国3家不同医院进行。对67例无远处转移的IBC患者的临床结局、病理特征和治疗策略进行了分析。采用卡方检验和单因素方差分析评估不同亚型之间的结局。采用Kaplan-Meier法分析总生存期（OS），采用Cox回归模型进行多因素分析。
整个队列的2年OS率为55%。腔面A型患者的中位OS时间为35个月，腔面B型为30个月，HER-2阳性型为24个月，三阴性亚型为20个月，彼此之间有显著差异（p=0.001）。多因素分析显示，与三阴性亚型相比，腔面A型死亡风险降低76%（p=0.037），腔面B型降低54%（p=0.048），HER-2阳性亚型降低47%（p=0.032）。此外，Ki-67标记升高与死亡风险增加相关，而手术治疗显著提高了患者生存率。
乳腺癌亚型与IBC患者的不同结局相关。三阴性IBC患者的预后比腔面A型、腔面B型和HER-2亚型患者差。这些结果表明，IBC是一种与传统乳腺癌相似的异质性疾病。
